BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
US bishops officially ban gender-affirming care at Catholic hospitals - 2Brilliant and Gleaming: Excellence and Skincare Practices
- 3Vote in favor of your #1 sort of juice
- 4The Development of Shipping: Controlling Towards a More Associated Future
- 5Opening Your True capacity: 12 Techniques for Personal growth
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- UN panel says Israel operating 'de facto policy of torture'
- The Meaning of Breaking the Pen's Nib in Death penalties
- Instructions to Explore the Universe of Vehicle Leases
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Anger as German family business group opens talks with far-right AfD
- Vote in favor of Your #1 Climbing boots Now
- How Would You Like to Deal with Your Funds?
